This inventor holds 2 USPTO granted patents, plus 4 CIPO patents and 1 EPO patent. Top assignees: Dso National Laboratories, National University of Singapore. Active years: 2016-2019.
Company Filing History:
2 out of 14 
2 out of 850 
Years Active: 2016-2019
Title: Shee Mei Lok: Innovator in Dengue Virus Research
Introduction
Shee Mei Lok is a notable inventor based in Singapore, recognized for his contributions to the field of medical research, particularly in the development of treatments for dengue virus infections. With a total of two patents to his name, he has made significant strides in the fight against this viral disease.
Latest Patents
His latest patents include a human monoclonal antibody with specificity for dengue virus serotype 1 E protein. This invention provides compositions and methods for the treatment or prevention of dengue virus infection in vertebrate subjects. Specifically, it discloses human neutralizing monoclonal antibodies to dengue virus that are isolated from EBV immortalized B cells derived from patients who have recovered from dengue infection. The methods outlined in the patent detail how to administer such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.
Career Highlights
Shee Mei Lok has worked with prestigious institutions such as the National University of Singapore and DSO National Laboratories. His work in these organizations has allowed him to contribute to significant advancements in medical research and innovation.
Collaborations
Some of his notable coworkers include Paul Macary and Ee Ping Evelyn Teoh, who have collaborated with him on various research projects.
Conclusion
Shee Mei Lok's innovative work in developing treatments for dengue virus infections showcases his dedication to advancing medical science. His contributions are vital in the ongoing battle against viral diseases, and his patents reflect the potential for significant impact in public health.